tbuckley/cabot-search huggingface dataset:
Ross Procedure in Infants and Toddlers Followed Into Childhood
Authors: Ismee A. Williams, Jan M. Quaegebeur, Daphne T. Hsu, Welton M. Gersony, Francois Bourlon, Ralph S. Mosca, Deborah R. Gersony, David E. Solowiejczyk
Journal: Circulation (2005)

Background— The Ross procedure is commonly used to treat aortic valve disease in pediatric and adult patients. For infants, data are limited regarding survival, reintervention, autograft growth, and function. Methods and Results— The Ross procedure was performed in 27 infants &lt;18 months of age (median age 5.7 months). All patients had congenital aortic stenosis (AS); associated lesions included subAS (n=9), supravalvular AS (n=2), coarctation (n=5), and interrupted aortic arch (n=2). Median follow-up was 6.1 years (range 0.2 to 12.9). There were 3 early deaths and no late deaths. Freedom from reintervention for homograft dysfunction was 87% at 8 years; freedom from autograft reintervention was 100%. Follow-up echocardiograms were available in 17 patients. Estimated peak autograft gradient was 55 mm Hg in one patient and &lt;10 mm Hg in 16. Mild autograft insufficiency was seen in 4 patients; 13 had none. Autograft diameter was measured early postoperatively and at latest follow-up. The mean z score increased from 0.63 to 3.2 ( P &lt;0.01) at the annulus and from 0.26 to 2.2 ( P &lt;0.01) at the sinus. In a subgroup, the mean autograft z score increased significantly from the postoperative period to 1 year for both the annulus (0.72 to 3.2, P &lt;0.01) and the sinus (0.26 to 2.2, P &lt;0.01), but remained unchanged thereafter. Conclusions— The Ross procedure effectively relieves AS in infants. Homograft reintervention occurred in 13% within 8 years. No patient developed significant autograft insufficiency or required autograft reintervention during the follow-up period. Dilatation of the autograft occurred during the first year after surgery and stabilized thereafter.
Minimal residual disease in hairy cell leukemia patients treated by BL22
Authors: Eugeny Arons, Joel Sunshine, Tara Suntum, Inger Margulies, Lynn Sorbara, Mark Raffeld, Maryalice Stetler-Stevenson, Ira Pastan, Robert J. Kreitman
Journal: Clinical Cancer Research (2006)

A51   Purine analogs induce long term complete remission in hairy cell leukemia (HCL) patients, but do not appear to be curative. For quantification of minimal residual disease (MRD) in patients after anti-CD22 recombinant immunotoxin BL22 and other agents, we used a relative quantitative PCR (RQ-PCR) assay using a TaqMan patient-specific primer and probe combination for the immunoglobulin heavy chain junction expressed in HCL cells. The sensitivity of this method makes it possible to detect 1 Bonna-12 HCL cell in either 106 Jurkat cells or in 106 normal mononuclear cells. We cloned, sequenced, and characterized the junction region from 23 HCL patients. We studied 84 samples from 10 patients for MRD, taken before or after treatment with BL22 and other agents. Patient-specific RQ-PCR was much more sensitive than flow cytometry, which in turn was (as recently reported) more sensitive than PCR using consensus primers. RQ-PCR was positive in 62 (100%) out of 62 flow-positive samples in 10 patients, and in 20 (91%) out of 22 flow-negative samples in 6 patients. The relative level of MRD as quantified by RQ-PCR correlated with disease status, remission, and relapse. Thus patient-specific RQ-PCR is the most sensitive test for MRD in HCL patients, and could be used to determine maximal response in patients obtaining multiple cycles of non-myelotoxic biologic treatment for this disease.
Abstract 12890: Epigenetic Modulation of Endothelial Cell Responses to Hypoxia and Post-ischemic Angiogenesis by the Component of Polycomb Repressive Complex 2 (PRC2), Enhancer of Zest Homology (EZH2)
Authors: Tijana Mitic, Orchi Anannya, Costanza Emanueli
Journal: Circulation (2013)

The enhancer of zest homology (EZH2) is the key enzymatic component of polycomb complex 2 (PRC2) along with the suppressor of zest 12 homolog (SUZ12). EZH2 induces the trimethylation of lysine 27 o...
Manuel technique de microbiologie et sérologie.
Authors: Albert Calmette
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 14731: Glyc A, a Novel Marker of Inflammation, Predicts Cardiovascular Events in HIV-Positive Patients: Results of SMART Study
Authors: Daniel Duprez, Jacqueline Neuhaus, James Otvos, James D Neaton, Jens D Lundgren
Journal: Circulation (2014)

Background: Cardiovascular disease (CVD) is increasing in HIV-infected patients. Glyc A is a novel nuclear magnetic resonance (NMR) spectroscopy signal in plasma arising from the glycosylation of circulating acute phase proteins. The acute phase proteins have been independently associated with CVD in HIV patients, but the association of Glyc A and CVD has not been studied. We aimed to quantify the risk of CVD associated with Glyc A at baseline in HIV-positive patients enrolled in the Strategies for Management of Anti-Retroviral Therapy (SMART) study. Methods: In a nested case-control study, Glyc A was measured using NMR at baseline in 246 HIV positive patients [median age, interquartile range (IQR): 49 (44,56) years, 81 % male], who experienced a CVD event (defined as coronary heart disease (CHD), myocardial infarction, coronary artery disease requiring revascularization, atherosclerotic non-CHD (stroke and peripheral arterial disease), congestive heart failure and CVD or unwitnessed death) over an average of 2.8 years of follow-up and 472 matched controls. Odds ratios (ORs) associated with baseline levels of Glyc A for CVD were estimated using conditional logistic regression unadjusted and after adjustment for BMI, race, HIV-RNA and antiretroviral therapy status, smoking, prior CVD, diabetes, total/high-density lipoprotein cholesterol ratio, use of blood pressure and lipid-lowering drugs, hepatitis co-infection, CD4+ and major baseline ECG abnormalities. Results: At baseline median Glyc A (IQR) was 383 (333, 442) μmol/L in patients who developed a CVD event and 368 (322, 419) μmol/L in controls (P &lt; 0.001 for difference). The unadjusted OR for CVD (highest versus lowest quartile) was 2.18 (with 95% confidence interval (CI) 1.38-3.44, P &lt; 0.001). After adjustment for baseline covariates and CVD risk factors, OR was 2.20 (95% CI, 1.29-3.76, P = 0.004). Conclusion: Higher levels of Glyc A are associated with increased risk of CVD in HIV patients after considering established CVD risk factors.
Oxford Handbook of Clinical Specialties
Authors: Judith Collier, Murray Longmore, Keith Amarakone.
Journal: Annals of Internal Medicine (1992)

The <italic>Oxford Handbook of Clinical Specialties</italic> covers each of the 14 core medical specialties encountered through medical school and Foundation Programme rotations. Packed full of high-quality illustrations, boxes, tables, and classifications, it is ideal for use at the direct point of care, whether on the ward or in the community, and for study and revision. Each chapter is easy to read and filled with digestible information, with features including ribbons to mark your most-used pages and mnemonics to help you memorize and retain key facts, while quotes from patients help the reader understand each problem better, enhancing the doctor/patient relationship. With reassuring and friendly advice throughout, this is the ultimate guide for every medical student and junior doctor for each clinical placement, and as a revision tool. This new edition has been reordered to follow a logical progression through the specialties, starting with an examination of the subjects of obstetrics, gynaecology, and paediatrics before moving on to ophthalmology, ear, nose, and throat (ENT), and dermatology. Orthopaedics and trauma are explored, leading through to emergency medicine, pre-hospital emergency medicine, and anaesthesia. Psychiatry and general practice are discussed before moving on to eponymous syndromes, and the book is rounded off by a new final chapter on doctors’ health and performance. Key references are flagged throughout, and included in a separate online resource.
Brca1 is expressed in human microglia and is dysregulated in human and animal model of ALS
Authors: Harun Najib Noristani, Jean Charles Sabourin, Yannick Nicolas Gerber, Marisa Teigell, Andreas Sommacal, Maria dM Vivanco, Markus Weber, Florence Evelyne Perrin
Journal: Molecular Neurodegeneration (2015)

There is growing evidence that microglia are key players in the pathological process of amyotrophic lateral sclerosis (ALS). It is suggested that microglia have a dual role in motoneurone degeneration through the release of both neuroprotective and neurotoxic factors. To identify candidate genes that may be involved in ALS pathology we have analysed at early symptomatic age (P90), the molecular signature of microglia from the lumbar region of the spinal cord of hSOD1G93A mice, the most widely used animal model of ALS. We first identified unique hSOD1G93A microglia transcriptomic profile that, in addition to more classical processes such as chemotaxis and immune response, pointed toward the potential involvement of the tumour suppressor gene breast cancer susceptibility gene 1 (Brca1). Secondly, comparison with our previous data on hSOD1G93A motoneurone gene profile substantiated the putative contribution of Brca1 in ALS. Finally, we established that Brca1 protein is specifically expressed in human spinal microglia and is up-regulated in ALS patients. Overall, our data provide new insights into the pathogenic concept of a non-cell-autonomous disease and the involvement of microglia in ALS. Importantly, the identification of Brca1 as a novel microglial marker and as possible contributor in both human and animal model of ALS may represent a valid therapeutic target. Moreover, our data points toward novel research strategies such as investigating the role of oncogenic proteins in neurodegenerative diseases.
Abstract 3447: The Breast Cancer Resistance Protein (BCRP) 421C> A Single Nucleotide Polymorphism Predicts Improved Low-Density-Lipoprotein Cholesterol Reduction by Rosuvastatin
Authors: Simon P Romaine, Anthony J Balmforth, Kristian M Bailey, Alistair S Hall
Journal: Circulation (2008)

Genetic differences in hepatic transporters may alter the concentration of hydrophilic statins at their site of action within hepatocytes, influencing clinical efficacy. Breast cancer resistance pr...
Oseltamivir-resistant influenza A(H1N1) viruses detected in Europe during season 2007-8 had epidemiologic and clinical characteristics similar to co-circulating susceptible A(H1N1) viruses
Authors: B  C Ciancio, T J Meerhoff, P Kramarz, I Bonmarin, K Borgen, C A Boucher, U Buchholz, S Buda, F Dijkstra, S Dudman, S Duwe, S H Hauge, O Hungnes, A Meijer, J Mossong, W  J Paget, N Phin, M van der Sande, B Schweiger, A Nicoll
Journal: Eurosurveillance (2009)

During the 2007-08 influenza season, high levels of oseltamivir resistance were detected among influenza A(H1N1) viruses in a number of European countries. We used surveillance data to describe influenza A(H1N1) cases for whom antiviral resistance testing was performed. We pooled data from national studies to identify possible risk factors for infection with a resistant virus and to ascertain whether such infections led to influenza illness of different severity. Information on demographic and clinical variables was obtained from patients or their physicians. Odds ratios for infection with an oseltamivir resistant virus and relative risks for developing certain clinical outcomes were computed and adjusted through multivariable analysis. Overall, 727 (24.3%) of 2,992 tested influenza A(H1N1) viruses from 22 of 30 European countries were oseltamivir-resistant. Levels of resistance ranged from 1% in Italy to 67% in Norway. Five countries provided detailed case-based data on 373 oseltamivir resistant and 796 susceptible cases. By multivariable analysis, none of the analysed factors was significantly associated with an increased risk of infection with an oseltamivir-resistant virus. Similarly, infection with an oseltamivir-resistant virus was not significantly associated with a different risk of pneumonia, hospitalisation or any clinical complication. The large-scale emergence of oseltamivir-resistant viruses in Europe calls for a review of guidelines for influenza treatment.
Association of systemic inflammation with clinical recovery in patients with acute exacerbation of COPD
Authors: Anant Mohan, Dharmendra Prasad, Alpana Sharma, Randeep Guleria, S.K. Sharma
Journal: European Respiratory Journal (2011)

Background: The association between changes in inflammatory markers and clinical response in acute exacerbations of COPD (AECOPD) is poorly defined.

Methods: Serum levels of Interleukin-6 (IL-6), High sensitivity C-reactive protein (Hs-CRP), and Fibrinogen were measured in patients with AECOPD at the time of admission and one month after discharge (stable state) and correlated with mortality and indices of disease severity.

Results: Out of 53 patients admitted with AECOPD during the study period, mortality was 28.4%. Patients who died were older, had significantly higher baseline serum IL-6, Hs-CRP, and Fibrinogen, higher smoking index, APACHE-II and SAPS-II scores. The 38 survivors were mostly males (82%), with mean (SD) age 63(8) years, mean (SD) duration of COPD of 11 (5) years, and mean (SD) smoking index of 288 (75). Majority (29/38) had type I exacerbation. Of these, 33 patients completed one month follow up assessment and demonstrated normalization of arterial blood gases, leucocyte counts and acute symptoms. They had a significant decline in serum IL-6 (152.5 and 14.05 pg/ml, p=0.001), Hs-CRP (18.2 and 3.5 mg/L, p=0.001), and Fibrinogen (46.3 and10.4 g/L, p=0.001) respectively from baseline till the stable state though the levels remained above the normal cutoffs. However, there was no statistically significant correlation between the change in the inflammatory markers with various indices of clinical and laboratory recovery from acute episode.

Conclusion: Although the initial surge in systemic inflammatory activity in AECOPD declines with recovery, the rate of normalization seems to lag behind the other conventional indices of disease activity and severity.
Anti‐acid medication as a risk factor for food allergy
Authors: I. Pali‐Schöll, E. Jensen‐Jarolim
Journal: Allergy (2010)

To cite this article: Pali‐Schöll I, Jensen‐Jarolim E. Anti‐acid medication as a risk factor for food allergy. Allergy 2011; 66 : 469–477. Abstract An important feature for oral allergens is their digestion‐resistance during gastrointestinal transit. For some oral allergens, digestion stability is an innate feature, whereas digestion‐labile antigens may only persist in times of impairment of the digestive system. In this review, we collect evidence from mouse and human studies that besides the inherent molecular characteristics of a food protein, the stomach function is decisive for the allergenic potential. Gastric acid levels determine the activation of gastric pepsin and also the release of pancreatic enzymes. When anti‐ulcer drugs inhibit or neutralize gastric acid, they allow persistence of intact food allergens and protein‐bound oral drugs with enhanced capacity to sensitize and elicit allergic reactions via the oral route. Mouse studies further suggest that maternal food allergy arising from co‐application of a food protein with anti‐acid drugs results in a Th2‐biased immune response in the offspring. Especially, anti‐ulcer drugs containing aluminum compounds act as Th2 adjuvants. Proton pump inhibitors act on proton secretion but also on expression of the morphogen Sonic hedgehog, which has been related to the development of atrophic gastritis. On the other hand, atrophic gastritis and resulting hypoacidity have previously been correlated with enhanced sensitization risk to food allergens in elderly patients. In summary, impairment of gastric function is a documented risk factor for sensitization against oral proteins and drugs.
Geographic origin and other determinants of site of tuberculosis disease in European countries
Authors: Nicolas Lefebvre, Dennis Falzon, Vahur Hollo, Marieke van der Werf, Andreas Sandgren, Giovanni Sotgiu
Journal: European Respiratory Journal (2014)

Background: The site of disease in tuberculosis (TB) influences transmissibility, diagnosis and treatment outcome. We explored host-related risk factors for site of TB disease using variables routinely collected for national surveillance by the European Centre for Disease Prevention and Control (ECDC).  Methods: Logistic and multinomial regression models were fitted to non-nominal case-based data to identify determinants of site of disease from among age, sex, previous TB diagnosis, country of report and geographic area of origin.  Results: Between 2003 and 2012, 24 European Union / European Economic Area countries reported a total of 406,673 TB cases with exclusive pulmonary (PTB; 82%) or extrapulmonary (EPTB; 18%) TB disease, and who had full data on all 5 explanatory variables. EPTB was associated with age   Conclusions: Awareness of host-related determinants of site of TB is pertinent to diagnostics. The predilection for extra-pulmonary TB localisation among patients originating from outside Europe may reflect ethnic differences in disease manifestations and higher HIV prevalence.
Sex: What We Make of It
Authors: Reed Edwin Pyeritz
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Textbook of Family Practice.
Authors: Robert E. Rakel
Journal: Annals of Internal Medicine (1984)

A practical resource which provides all the information needed for optimal patient care in family practice. Organized by presenting symptoms, this edition adopts a humanistic and problem-oriented approach to primary care. Packed with practical management skills, technological advances in office management and information on maintaining problem-oriented medical records that can increase office efficiency, it also covers family structure, impact of illness on the family, impact of divorce, elder and spouse abuse, genetic problems economics of family practice and more.
The Surgeon's Log. Impressions of the Far East.
Authors: James Johnston Abraham
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Production of Malignancy <italic>in vitro</italic>. IX. Description of Cells at the Fluid Interface of the Culture<xref ref-type="fn" rid="fn1"><sup>2</sup></xref>
Authors: Wilton R. Earle, Edward L. Schilling, Emma Shelton
Journal: JNCI Journal of the National Cancer Institute (1950)

Journal Article Production of Malignancy in vitro. IX. Description of Cells at the Fluid Interface of the Culture Get access Wilton R. Earle, Wilton R. Earle cytologist Search for other works by this author on: Oxford Academic PubMed Google Scholar Edward L. Schilling, Edward L. Schilling technologist Search for other works by this author on: Oxford Academic PubMed Google Scholar Emma Shelton Emma Shelton cytologist National Cancer Institute, National Institutes of Health, Public Health Service, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 10, Issue 4, February 1950, Pages 865–881, https://doi.org/10.1093/jnci/10.4.865 Published: 01 February 1950 Article history Received: 07 October 1949 Published: 01 February 1950